Our findings demonstrate that the riskScore serves as a statistically robust prognostic tool, surpassing the established clinical systems such as BCLC, ALBI, CLIP, and AFP in predicting outcomes in patients with HCC. The gene discussed is AFP; the disease is hepatocellular carcinoma.